Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

    Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

    Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

    We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

    1. Home

    2. Press center
    3. Press releases
    4. Siemens Healthineers Hemoglobin A1c Test for Diagnosing and Monitoring Diabetes Now Available on the Atellica Solution
    Press release

    Siemens Healthineers Hemoglobin A1c Test for Diagnosing and Monitoring Diabetes Now Available on the Atellica Solution

    Published on May 15, 2019

    The Atellica® CH Enzymatic Hemoglobin A1c (A1c_E) Assay

    Download this press release(pdf, 541.35 KB)
    1

    Product availability varies by country.

    2

    Atellica CH A1c_E IFU. Siemens Healthcare Diagnostics Inc. 11111609_EN Rev. 01, 2019-01

    3

    The Atellica CH A1c_E assay is NGSP certified and an IFCC-standardized HbA1c assay that demonstrates < 5% change with most known Hb variants (HbC, HbD, HbE, HbS, and HbA2).

    4

    International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org

    Reference Number: PR-20190514018SHS

    Siemens Healthineers

    Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide.